A5045549096- Prostate Cancer Treatment and Research
- Radiopharmaceutical Chemistry and Applications
- CAR-T cell therapy research
- Palliative Care and End-of-Life Issues
- Medical and Health Sciences Research
- Bladder and Urothelial Cancer Treatments
- Ethics in medical practice
- Acute Myeloid Leukemia Research
- Neutropenia and Cancer Infections
- Chronic Myeloid Leukemia Treatments
- Patient Dignity and Privacy
- Urinary and Genital Oncology Studies
- Cancer Immunotherapy and Biomarkers
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cancer survivorship and care
- Clinical practice guidelines implementation
- Immunotherapy and Immune Responses
- Helicobacter pylori-related gastroenterology studies
- Monoclonal and Polyclonal Antibodies Research
- Cancer Diagnosis and Treatment
- Childhood Cancer Survivors' Quality of Life
- Multiple Myeloma Research and Treatments
- Acute Lymphoblastic Leukemia research
Hospital of the Brothers of St. John of God
2009-2024
Barmherzige Schwestern Krankenhaus Wien
2012-2024
Convent Hospital of the Brothers of Saint John of God
2016-2024
Krankenhaus Barmherzige Brüder
2007-2008
Krankenanstalt Rudolfstiftung der Stadt Wien
2007
Landeskrankenhaus Feldkirch
2007
Ordensklinikum Linz Barmherzige Schwestern
2007
Wilhelminen Hospital
1998-2007
Vienna General Hospital
2007
Leipzig University
2004
Abstract Purpose: Safety and efficacy of acapatamab, a prostate-specific membrane antigen (PSMA) x CD3 bispecific T-cell engager were evaluated in first-in-human study metastatic castration-resistant prostate cancer (mCRPC). Patients Methods: with mCRPC refractory to androgen receptor pathway inhibitor therapy taxane-based chemotherapy received target acapatamab doses ranging from 0.003 0.9 mg dose exploration (seven levels) 0.3 (recommended phase II dose) expansion intravenously every 2...
In comparison to chemotherapy, enfortumab vedotin (EV) prolonged overall survival in patients with previously treated advanced urothelial carcinoma EV-301. The objective of the present study was assess patient experiences EV versus chemotherapy using patient-reported outcome (PRO) analysis health-related quality life (HRQoL). For phase 3 EV-301 trial randomized or we assessed responses validated European Organisation for Research and Treatment Cancer Quality Life Questionnaire Core 30...
Paraprotein induced renal failure is a frequent complication of multiple myeloma and associated with poor survival. Previously, reversal function has been hampered by the lack fast acting highly effective therapy most patients remained or became dependent on hemodialysis. Here we show acute paraprotein-induced bortezomib-based in 5 out 8 patients. Improvement was preceded significant reduction paraprotein concentration all patients, improvement function.
<b><i>Background:</i></b> Neoadjuvant chemotherapy with methotrexate-vinblastine-doxorubicin-cisplatin (MVAC) is the standard of care for muscle-invasive urothelial bladder cancer. Gemcitabine plus cisplatin (GC) shows similar efficacy less toxicity in metastatic setting and has therefore often been used interchangeably MVAC. We report on safety neoadjuvant GC patients locally advanced <b><i>Materials Methods:</i></b> prospectively evaluated 87...
Importance The oral pan–fibroblast growth factor receptor inhibitor rogaratinib previously demonstrated encouraging safety and efficacy in a phase 1 study of patients with urothelial cancer (UC) overexpressing FGFR messenger RNA (mRNA). Objective To evaluate the safety, pharmacokinetics, preliminary combination programmed cell death ligand (PD-L1) atezolizumab cisplatin-ineligible mRNA-positive, locally advanced/metastatic UC. Design, Setting, Participants FORT-2 nonrandomized clinical trial...
Die Palliative Sedierungstherapie (PST) ist eine wichtige und ethisch akzeptierte Therapie in der Versorgung von ausgewählten sterbenden Menschen, welche aufgrund therapierefraktärer Symptome für sie unerträgliches Leiden erleben. PST findet zunehmend Anwendung Betreuung Sterbender. In Östereich gibt es keine standardisierte fundierte Leitlinie diese exzeptionelle Therapie, liegen jedoch Beweise vor, dass die angewandte Praxis bundesweit sehr uneinheitlich ist. Im Auftrag Österreichischen...
<p>Study scheme</p>
Chromosome aberrations affecting band 3q21 are associated with a particularly poor prognosis in patients acute myeloid leukaemia. To facilitate the molecular characterization of such rearrangements, we established PAC contig covering relevant genomic region. Using these PACs as probes fluorescence situ hybridization (FISH) experiments, showed that number breakpoints patient samples map to previously defined ‘breakpoint cluster region’. Others, however, located at varying distances...
We report a case of idiopathic myelofibrosis with trisomy 13 as the sole clonal aberration, demonstrated by metaphase cytogenetics. The clinical course was especially poor in this case, death blast crisis occurring within two weeks from diagnosis. dismal outcome bears striking similarity to previous cases and reported literature. Therefore may be predictor rapidly fatal otherwise indolent disease. Fluorescence situ hybridisation (FISH) chromosome specific probe enhance detection since only...
441 Background: Nivolumab (nivo) is an approved 2 nd line treatment after platinum-based chemotherapy in metastatic urothelial carcinoma (mUC). Recent studies suggest improved outcomes for dual checkpoint inhibition mUC particular with higher ipilimumab (ipi) doses (nivo 1mg/kg + ipi 3mg/kg). TITAN-TCC uses a response-based approach starting 4 of nivo (8 weeks) followed by nivo+ipi boosts non-responders. Here we report cohort applying nivo1/ipi3 boost patients prior (2 /3 rd line). Methods:...
Aufgrund der epidemiologischen Entwicklung werden onkologische Patienten mit Demenz quantitativ stark zunehmen. als Komorbidität darf eine indizierte Therapie nicht grundsätzlich verhindern, sondern erfordert sorgfältige Prüfung Gesamtsituation. Die entscheidende Frage Indikation ist die nach dem Therapieziel, zu dann endgültige Zustimmung ("informed consent") erfolgen muss. Fürsorgepflicht wird bei fehlender Entscheidungsfähigkeit überwiegen und Therapieziele im wohlverstandenen Interesse...
<div>AbstractPurpose:<p>Safety and efficacy of acapatamab, a prostate-specific membrane antigen (PSMA) x CD3 bispecific T-cell engager were evaluated in first-in-human study metastatic castration-resistant prostate cancer (mCRPC).</p>Patients Methods:<p>Patients with mCRPC refractory to androgen receptor pathway inhibitor therapy taxane-based chemotherapy received target acapatamab doses ranging from 0.003 0.9 mg dose exploration (seven levels) 0.3 (recommended phase...
<div>AbstractPurpose:<p>Safety and efficacy of acapatamab, a prostate-specific membrane antigen (PSMA) x CD3 bispecific T-cell engager were evaluated in first-in-human study metastatic castration-resistant prostate cancer (mCRPC).</p>Patients Methods:<p>Patients with mCRPC refractory to androgen receptor pathway inhibitor therapy taxane-based chemotherapy received target acapatamab doses ranging from 0.003 0.9 mg dose exploration (seven levels) 0.3 (recommended phase...
<p>Supplementary Methods</p>
<p>Best (unconfirmed) prostate-specific antigen response in dose exploration</p>